Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0GJLAS)
| ADC Name |
ARX305
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
ARX305; NCB002; JNJ-0631
Click to Show/Hide
|
|||||
| Organization |
Ambrx (Top20 MNC) (Originator);NovoCodex Biopharmaceuticals
|
|||||
| Drug Status |
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-CD70 mAb
|
Antibody Info | ||||
| Antigen Name |
CD70 antigen (CD70)
|
Antigen Info | ||||
| Payload Name |
Amberstatin 269 (AS269)
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Oxime-PEG3
|
Linker Info | ||||
| Conjugate Type |
Non-natural Amino Acids
|
|||||
| Combination Type |
amberstatin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Unspecific hematological malignancies |
1 Trials
|